A Phase II, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Nafithromycin Versus Oral Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults

Trial Profile

A Phase II, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Nafithromycin Versus Oral Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Nafithromycin (Primary) ; Moxifloxacin
  • Indications Community-acquired pneumonia
  • Focus Therapeutic Use
  • Sponsors Wockhardt
  • Most Recent Events

    • 22 Sep 2017 This trial has been completed in Latvia (end date: 8 Jul 2017).
    • 17 Sep 2017 This study has been completed in Bulgaria as per European Clinical Trials Database.
    • 08 Jun 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top